CDMO: Avid Bioservices Inc Company Value to Net Income

The Avid Bioservices, Inc. (CDMO) business relies on the moderately cyclical production of biologics, where long-term contracts smooth out economic fluctuations, and the current metric stands at -5.20. The company's price evolution confirms this resilience. Avid Bioservices, Inc. minimizes risks by collaborating with various pharmaceutical manufacturers in drug development. Furthermore, the firm optimizes the procurement of single-use bioreactors by expanding its supplier base to ensure uninterrupted line operations.

CDMO: Avid Bioservices, Inc P/E Multiple 07/04/2022 - 02/16/2025

Analytical breakdowns for Avid Bioservices, Inc (CDMO)

- price and consensus price forecast:

Stock Price Avid Bioservices, Inc|CDMO - Consensus Target

- market capitalization information:

Market Value Avid Bioservices Inc|CDMO - Real Price to Acquire Entire Company

- balance sheet net asset value indicators:

Book Price of a Share Avid Bioservices|CDMO - Book Capitalization|Market-to-Book Ratio avidbio.com|CDMO - Aggregate Company Assets

- debt obligations and liquidity statistics:

- earnings and valuation multiples information:

CDMO - Net Profit|Company Profit Forecast Avid Bioservices, Inc.|CDMO - P/E Multiple|Price to Future Earnings Ratio Avid Bioservices, Inc.|CDMO - Price/Earnings to Growth Multiple|Business Value to Operating Income Before Depreciation Avid Bioservices Inc.|CDMO - Operating profit EBITDA|Earnings per share for the last twelve months Avid Bioservices|CDMO - Net earnings per share (EPS TTM)|Year-over-year net earnings per share change for the last twelve months avidbio.com|CDMO - Earnings per share growth in current year|Expected net earnings per share growth next year Avid Bioservices, Inc.

- company sales and revenue statistics:

CDMO - Company Revenue|Company Future Sales Avid Bioservices|CDMO - P/S Multiple|Market Cap to Future Revenue Ratio Avid Bioservices, Inc|CDMO - Sales Growth YoY (Last Twelve Months)

Comprehensive company analysis:Avid Bioservices, Inc.

Manufactured product of Avid Bioservices Inc.

Investors are seeking to protect capital from volatility by searching for fundamentally undervalued assets. The implementation of AI-controlled bioreactor robotics at Avid Bioservices, Inc. (CDMO) reduces operating expenses, ensuring business resilience. The company's current market P/E ratio, standing at -5.20, reflects the investment payback period through the ratio of share price to net income. This multiple measures market expectations and the degree of business overvaluation amid tight monetary policy. A decrease in this indicator signals the formation of a safe entry point for a portfolio.

Key competitors